№ files_lp_4_process_3_084060
File format: docx
Character count: 27697
File size: 77 KB
This document is a protocol for tracking SARS-CoV-2 infections among healthcare personnel to study the incidence of COVID-19, risk factors, and preventive measures in U.S. healthcare facilities.
Year:
2020
Region / city:
United States
Topic:
Healthcare personnel, SARS-CoV-2, COVID-19
Document Type:
Protocol
Organization:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
Centers for Disease Control and Prevention (CDC)
Target Audience:
Healthcare personnel, public health officials, researchers
Period of Validity:
Ongoing
Approval Date:
April 22, 2020
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Region / city:
Global
Theme:
COVID-19 Pandemic, Health Risk Assessment
Document type:
Report
Organization:
Centers for Disease Control and Prevention (CDC), World Health Organization (WHO)
Author:
Centers for Disease Control and Prevention (CDC)
Target audience:
Public health officials, healthcare providers, researchers
Validity period:
Ongoing
Approval date:
October 19, 2020
Date of changes:
Ongoing
Year:
2020
Region / City:
New South Wales, Australia
Topic:
Biology, SARS-CoV-2, RNA, Vaccination, Infectious Diseases
Document Type:
Educational Resource
Organization / Institution:
New South Wales Education Standards Authority (NESA)
Author:
Not specified
Target Audience:
Year 12 students
Period of Validity:
2020 and onwards
Approval Date:
2017
Date of Changes:
Not specified
Year:
2021
Region / city:
United States
Topic:
COVID-19, occupational health, risk assessment
Document type:
Report
Organization / institution:
CSTE Occupational Health Subcommittee
Author:
CSTE Occupational Health Subcommittee, Work Group on Essential Workers - Exposure Measures Team
Target audience:
Epidemiologists, policymakers, occupational health experts
Effective period:
From August 18, 2021
Approval date:
August 18, 2021
Date of changes:
August 18, 2021
Year:
2020
Region:
Guangdong Province, China
Topic:
Genomic epidemiology of SARS-CoV-2
Document type:
Supplementary information to a scientific research article
Associated article:
Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China
Authors:
Jing Lu; Louis du Plessis; Zhe Liu; Verity Hill; Min Kang; Huifang Lin; Jiufeng Sun; Sarah François; Moritz U G Kraemer; Nuno R Faria; John T McCrone; Jingju Peng; Qianlin Xiong; Runyu Yuan; Lilian Zeng; Pingping Zhou; Chuming Liang; Lina Yi; Jun Liu; Jianpeng Xiao; Jianxiong Hu; Tao Liu; Wenjun Ma; Wei Li; Juan Su; Huanying Zheng; Bo Peng; Shisong Fang; Wenzhe Su; Kuibiao Li; Ruilin Sun; Ru Bai; Xi Tang; Minfeng Liang; Josh Quick; Tie Song; Andrew Rambaut; Nick Loman; Jayna Raghwani; Oliver G Pybus; Changwen Ke
Affiliated institutions:
Guangdong Provincial Center for Disease Control and Prevention; University of Oxford; University of Edinburgh; Shenzhen Center for Disease Control and Prevention; Guangzhou Center for Disease Control and Prevention; Guangdong Provincial Second People’s Hospital; Foshan First People’s Hospital; University of Birmingham
Data coverage period:
Up to 19 March 2020
Number of reported genomes:
53 newly reported SARS-CoV-2 genomes
Total cases referenced:
1388 laboratory-confirmed COVID-19 cases
Figures:
S1–S4
Tables:
S1–S2
Data sources:
RT-PCR testing; whole-genome sequencing; GISAID database
Geographic scope of comparative data:
Guangdong; Hubei; USA (California, Wisconsin); Japan; Singapore; Jiangsu; Fujian; India; Vietnam
Year:
2021
Region / city:
Various locations in the United States
Topic:
COVID-19 Treatment
Document type:
Clinical Trial Report
Institution:
Regeneron Pharmaceuticals, NIAID/CoVPN
Author:
Multiple investigators and research teams
Target audience:
Healthcare professionals, researchers, clinical trial coordinators
Period of validity:
Study conducted during 2020-2021
Approval date:
Not specified
Date of changes:
Not specified
Document Type:
Supplementary data appendix
Subject:
Development and validation of a rapid viability RT-PCR (RV-RT-PCR) method for detection of infectious SARS-CoV-2
Pathogen:
SARS-CoV-2
Experimental Model:
Vero E6 cells
Institutions:
U.S. Environmental Protection Agency, Office of Research and Development; Lawrence Livermore National Laboratory
Authors:
Sanjiv R. Shah; Staci R. Kane; Maher Elsheikh; Teneile M. Alfaro
Geographic Location:
Washington, District of Columbia, USA; Livermore, California, USA
Data Type:
RT-PCR cycle threshold (CT) measurements; plaque forming units (PFU); TCID50 values; recovery efficiency data
Infection Conditions:
1-hour and 2-hour infection periods with post-infection incubation at T0, T12, and T24
Sample Type:
SARS-CoV-2-infected cell cultures and swab swatches
Analytical Replicates:
Triplicate RT-PCR analyses with pooled standard deviations
Tables Included:
Table S1; Table S2; Table S3; Table S4
Year:
2022
Region / City:
N/A
Subject:
Molecular interaction studies
Document Type:
Supplementary data
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers in biochemistry, molecular biology, and virology
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2021
Study type:
Clinical research
Document type:
Supplementary materials
Authors:
Not specified
Institution:
Not specified
Target audience:
Researchers in oncology and virology
Tumor types:
Glioma, Meningioma, Pituitary adenoma, Craniopharyngioma, Ependymoma, Schwannoma, Haemangioblastoma, Chordoma, Brain metastases from breast, lung, kidney, colon cancer
Methods:
Immunohistochemistry, Immunofluorescence, Gene expression analysis, KEGG enrichment, GSEA
Patient information:
Age, Sex, Preexisting conditions, Preoperative treatment, SARS-CoV-2 PCR status
Figures included:
S1–S6
Tables included:
S1
Key markers analyzed:
ACE2, TMPRSS2, CD147, NRP1, IFN-γ, PD-1, FOXP3, CD8, CD4, C1q, C3, IgG, IgM, CD68, TTF1, MUC1
Year:
2026
Region / Institution:
Not specified
Topic:
Immunology, SARS-CoV-2, Vaccine Response
Document type:
Peer Review
Author:
Stefania P Bjarnarson
Target audience:
Researchers, Immunologists
Study period:
Up to 33 months post mRNA vaccination
Methods:
Analysis of bone marrow plasma cells, healthy adult donors, post-vaccination sampling
Key findings:
Limited presence of SARS-CoV-2-specific long-lived plasma cells in bone marrow after mRNA vaccination or hybrid immunity
Data source:
Bone marrow aspirates, hip joint replacement surgery samples
Limitations:
Small sample size, discrepancies in patient description, consideration of asymptomatic infections
Scientific relevance:
Provides evidence on the longevity of humoral immune response post-vaccination
Concise description:
Peer-reviewed evaluation of a study assessing the presence of SARS-CoV-2-specific long-lived plasma cells in the bone marrow following mRNA vaccination and hybrid immunity, highlighting methodology, key results, and points for revision.
Year:
2020
Region / city:
United States, multiple states
Theme:
SARS-CoV-2, Healthcare personnel, COVID-19
Document type:
Protocol
Organization / institution:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
CDC Division of Healthcare Quality Promotion
Target audience:
Healthcare personnel, public health professionals, researchers
Period of action:
2020
Date of approval:
July 17, 2020
Date of changes:
Not specified
Context description:
Protocol for tracking SARS-CoV-2 infections and assessing risks among healthcare personnel in the United States during the COVID-19 pandemic.
Year:
2026
Region / Country:
Global
Subject:
Veterinary virology, poultry diseases
Document type:
Scientific chapter
Institution / Organization:
Not specified
Target audience:
Veterinarians, poultry researchers, animal health specialists
Pathogen:
Avian metapneumovirus (aMPV)
Affected species:
Turkeys, chickens, ducks, pheasants, Muscovy ducks, Peking ducks, guinea fowl
Clinical signs:
Respiratory infection, reproductive disorders, swollen head syndrome, decreased egg production
Transmission:
Highly contagious, rapid spread through flocks
Diagnosis methods:
Virus isolation, RT-PCR, ELISA, immunofluorescence, virus neutralization
Serotypes / subgroups:
A, B, C, D
Public health relevance:
No human infections reported
Economic impact:
Losses in turkey and chicken flocks
Year:
2023
Region / City:
Australia
Theme:
Infectious Diseases Management, Healthcare
Document Type:
Guidelines
Organization:
Australian Government, Department of Health
Author:
Not specified
Target Audience:
Operators of residential care facilities
Action Period:
Ongoing
Approval Date:
16 May 2023
Amendment Date:
None
Context:
This document provides a comprehensive checklist for the management of acute respiratory infections, including COVID-19, influenza, and RSV, in residential care facilities.
Year:
1968
Region / City:
United Kingdom
Topic:
Vaccination, Measles, Immunology
Document Type:
Educational Text
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Students, Health professionals
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2021
Region / City:
United Kingdom
Subject:
Health economics, antimicrobial evaluation
Document type:
Final report
Organization / Institution:
Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author:
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience:
Healthcare professionals, policymakers, researchers
Period of validity:
2016 - ongoing
Approval date:
October 2021
Date of last modification:
October 2021
Year:
2022
Region / city:
United Kingdom
Topic:
Healthcare, Infectious Diseases, Antimicrobial Resistance
Document Type:
Briefing Paper
Organization / Institution:
National Institute for Health and Care Excellence
Author:
NICE
Target Audience:
Healthcare professionals, Policy makers, Researchers
Period of validity:
Not specified
Approval Date:
12th July 2022
Date of Changes:
Not specified
Year:
2023
Region / City:
Atlanta, GA
Topic:
Public Health, Infectious Diseases
Document Type:
Non-Substantive Change Request
Organization / Institution:
U.S. Centers for Disease Control and Prevention (CDC)
Author:
Sonja Mali Nti-Berko, MPH
Target Audience:
Public Health Professionals, Epidemiologists, Researchers
Period of Action:
2023-2026
Approval Date:
12/21/2023
Date of Modifications:
N/A
Year:
2022
Region / city:
United Kingdom
Subject:
Health care, Medical guidelines
Document type:
Quality standard
Organization / institution:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence (NICE)
Target audience:
Healthcare professionals, Service providers
Period of validity:
2022-2023
Approval date:
11 June 2015
Date of amendments:
6 September 2022
Note:
Contextual description
Year:
2021
Region/Country:
United Arab Emirates
Type of document:
Clinical guideline
Organization:
National Antimicrobial Stewardship Committee
Target population:
Adult outpatients, Adult inpatients, Pregnant women
Scope:
Empiric antibiotic management of urinary tract infections
Version:
1
Date of issue:
1 September 2021
Review period:
Every three years
Attachments:
Risk factors for complicated UTIs, Summary tables for empiric treatment, National cumulative antibiogram 2019
References:
CDC, IDSA, ESCMID, FDA standards
Year:
2021
Month:
August
Region:
England
Healthcare setting:
Primary care
Clinical area:
Paediatrics
Conditions covered:
Bronchiolitis; Viral induced wheeze; Viral lower respiratory tract infections
Document type:
Clinical guidance
Authors:
Clare Harris; Sanjay Patel; Zena Penny; David James; Sally Robins; Julia Shaw; Natalie Smith; Jo Borbone; Kathryn Bannell; Mark Alderton; Olie Morris; Sian Butterworth
Affiliated organisations:
Healthier Together; Hampshire CCGs; NHS England
Target audience:
Primary care clinicians
Patient population:
Infants and children
Referral pathways:
Primary to secondary care
Associated programmes:
Palivizumab programme
Guidance source:
Healthier Together clinical pathways
Year:
2018
Region / city:
Philadelphia, USA
Topic:
Biofilm-related musculoskeletal infections
Document type:
Summary report
Organization:
International Consensus Meeting on Musculoskeletal Infection
Author:
Kordo Saeed, Alex C. McLaren, Edward M. Schwarz, Valentin Antoci, William V. Arnold, Antonia F. Chen, Martin Clauss, Jaime Esteban, Vanya Gant, Edward Hendershot, Noreen Hickok, Carlos A. Higuera, Débora C. Coraça-Huber, Hyonmin Choe, Jessica Amber Jennings, Manjari Joshi, William T. Li, Philip C. Noble, K. Scott Phillips, Paul S. Pottinger, Camilo Restrepo, Holger Rohde, Thomas P. Schaer, Hao Shen, Mark Smeltzer, Paul Stoodley, Jason C. J. Webb, Eivind Witsø
Target audience:
Medical professionals, researchers, healthcare providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Context:
The document is a consensus report summarizing discussions and conclusions from the Biofilm Workgroup at the 2018 International Consensus Meeting on Musculoskeletal Infections, addressing clinical challenges related to biofilm-associated musculoskeletal infections.